A new EGFR‐TKI poziotinib is an irreversible pan‐HER TKI that targets EGFR, HER2, and HER4 and showed an ORR of 27.8% in second‐line therapy for NSCLC with EGFR exon 20 insertions in a phase II study (NCT03318939).167. This evidence concerns the gene EGFR and non-small cell lung carcinoma.